Molecule News and Research

RSS

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009.

6 Oct 2009

IBM scientists to build nanoscale DNA sequencer to read human DNA

In an effort to build a nanoscale DNA sequencer, IBM scientists are drilling nano-sized holes in computer-like chips and passing DNA strands through them in order to read the information contained within their genetic code.

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the Scripps Research Institute have uncovered the role played by the least-understood part of a first-responder molecule that rushes in to bind and repair breaks in DNA strands, a process that helps people avoid cancer.

5 Oct 2009

Nature's best mercury fighters: Bacteria

Mercury pollution is a persistent problem in the environment. Human activity has lead to increasingly large accumulations of the toxic chemical, especially in waterways, where fish and shellfish tend to act as sponges for the heavy metal.

5 Oct 2009

Study shows that GSK-3 gene determines the total number of neurons required for brain

In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.

5 Oct 2009

Researchers engineer antidotes for blood-thinner aptamers

Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. Researchers at Duke University Medical Center have engineered a way to do this for an entire, versatile class of drugs called aptamers and published their findings in Nature Medicine.

4 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

NEDD9 protein stimulates aggressive metastatic breast cancer

Researchers at Fox Chase Cancer Center have demonstrated that a protein called NEDD9 may be required for some of the most aggressive forms of breast cancer to grow. Their findings, based on the study of a mouse model of breast cancer, are presented in a recent issue of Cancer Research, available on-line now.

3 Oct 2009

Nasal spray to improve memory

Good news for procrastinating students: a nasal spray developed by a team of German scientists promises to give late night cram sessions a major boost, if a good night's sleep follows.

3 Oct 2009

Enzyme that helps make tuberculosis resistant to a human's natural defense system identified

Researchers at Iowa State University have identified an enzyme that helps make tuberculosis resistant to a human's natural defense system. Researchers have also found a method to possibly neutralize that enzyme, which may someday lead to a cure for tuberculosis.

3 Oct 2009

Arginetix raises funds for development programs

Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The company is developing small molecule inhibitors of the enzyme arginase for the treatment of endothelial dysfunction, including pulmonary arterial hypertension, atherosclerosis and asthma.

2 Oct 2009

Actavis' clients launch generic Atorvastatin in Spain

Actavis Group, the international generic pharmaceuticals company, today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market.

1 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

Solvay's decision to sell its Pharmaceuticals Sector does not affect Girindus

Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its Pharmaceuticals Sector to Abbott. Girindus is a member of Solvay Organics, which is part of the Chemicals Division of the Solvay Group and is therefore completely separate from the Pharmaceuticals Division.

1 Oct 2009

Brdt protein in developing sperm cells direct tight re-packaging of sperm DNA

In the quest for speed, olympic swimmers shave themselves or squeeze into high-tech super-suits. In the body, sperm are the only cells that swim and, as speed is crucial to fertility, have developed their own ways to become exceptionally streamlined. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Grenoble, the Institut de Biologie Structurale (IBS) and the Institut Albert Bonniot, both also in Grenoble, have been studying the secrets of speedy sperm.

1 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009